1. Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors

    Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors

    Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016....

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. Dan is an experienced biopharmaceutical leader who brings to REGENXBIO more than 25 years of success in key strategic, operational, legal and board roles.
    2. REGENXBIO's proprietary NAV Technology Platform has ushered in a new era of gene therapy innovation with the potential to transform the lives of patients suffering from serious diseases with unmet needs.
    3. I would like to recognize and thank Camille for her sound guidance and many contributions as an early investor in REGENXBIO.
  3. Topics Mentioned